The Department of Justice has announced a $14 million False Claims Act (FCA) settlement with Coloplast, a medical product manufacturer, after Coloplast self-disclosed violations of the Trade Agreements Act (TAA) and Price Reduction Clause (PRC) while under contract with the Department of Veterans Affairs (VA). The TAA requires contractors to furnish end products that are U.S.-made or "substantially transformed" in designated countries. Coloplast disclosed that it misapplied the substantial-transformation standard, causing Coloplast to report incorrect countries of origin for products and to improperly retain certain products on contract after manufacturing moved to non-designated countries. Coloplast also disclosed that it overbilled the Government by failing to provide the VA with discounts pursuant to the terms of the PRC, which normally requires tracking discounts offered to designated commercial customers and offering corresponding downward price adjustments to VA customers.
Clearly, Coloplast did not dispute that it had violated the TAA and PRC clauses in its contract with the VA. Unclear, however, are (1) to which government authorities Coloplast directed its self-disclosures and (2) whether Coloplast made those disclosures pursuant to the Mandatory Disclosure Rule applicable to government contractors. See FAR 52.203-13(b)(3). Also unclear is whether Coloplast received any credit in the settlement for having made these disclosures and for any subsequent cooperation...
Kevin Sabet, CEO of Smart Approaches to Marijuana, discusses a class-action lawsuit against Chicago cannabis companies for allegedly marketing products with false medical benefits on 'America's New...